68 Results for "

LMP

" in MedChemExpress (MCE) Product Catalog:
Products (68)

68 Results for "LMP" in MCE Product Catalog:

27
27 Publications Verification
Art. -Nr.: HY-13821
CAS. Nr.: 134381-21-8
Reinheit:  99.39%
Synonyms: BU-4061T
Epoxomicin (BU-4061T) is an epoxyketone-containing natural product and a potent, selective and irreversible proteasome inhibitor. Epoxomicin covalently binds to the LMP7, X, MECL1, and Z catalytic subunits of the proteasome and potently inhibits primarily the chymotrypsin-like activity. Epoxomicin can cross the blood-brain barrier. Epoxomicin has strongly antitumor and anti-inflammatory activity .
loading...
    loading...
26
26 Cited Publications
Art. -Nr.: HY-13207
CAS. Nr.: 960374-59-8
Reinheit:  99.72%
Synonyms: PR-957
Target:  

Proteasome Bacterial HIV

Forschungsgebiete:  

Infection Inflammation/Immunology

ONX-0914 (PR-957) is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 blocks cytokine production and attenuates progression of experimental arthritis. ONX-0914 is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (Ki=5.2 μM). ONX-0914 reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1 .
loading...
    loading...
26
26 Cited Publications
Art. -Nr.: HY-13207A
Reinheit:  98.01%
Synonyms: PR-957 TFA
Target:  

Proteasome Bacterial HIV

Forschungsgebiete:  

Infection Inflammation/Immunology

ONX-0914 (PR-957) TFA is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 TFA blocks cytokine production and attenuates progression of experimental arthritis. ONX-0914 TFA is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (Ki=5.2 μM). ONX-0914 TFA reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1 .
loading...
    loading...
5
5 Cited Publications
Art. -Nr.: HY-111790
CAS. Nr.: 2285330-15-4
Reinheit:  ≥98.0%
Target:  

Proteasome Apoptosis

Forschungsgebiete:  

Cancer

M3258 is an orally bioavailable, potent, reversible and highly selective immunoproteasome subunit LMP7 (β5i) inhibitor. M3258 exerts high biochemical (IC50=3.6 nM) and cellular (IC50=3.4 nM) potency against the LMP7 subunit. M3258 shows strong antitumor efficacy in multiple myeloma xenograft models. M3258 leads to a significant and prolonged suppression of tumor LMP7 activity and ubiquitinated protein turnover and the induction of apoptosis in multiple myeloma cells .
loading...
    loading...
5
5 Cited Publications
Art. -Nr.: HY-101786
CAS. Nr.: 1629052-78-3
Reinheit:  99.33%
Target:  

Proteasome

Forschungsgebiete:  

Inflammation/Immunology

KZR-504 is a highly selective inhibitor of immunoproteasome low molecular mass polypeptide 2 (LMP2), with IC50s of 51 nM, 4.274 μM for LMP2 and LMP7, respectively. KZR-504 is of interest for the treatment of autoimmune disease .
loading...
    loading...
4
4 Cited Publications
Art. -Nr.: HY-114419
CAS. Nr.: 1629677-75-3
Reinheit:  99.89%
Synonyms: KZR-616
Target:  

Proteasome

Forschungsgebiete:  

Inflammation/Immunology

Zetomipzomib (KZR-616), a first-in-class inhibitor of the immunoproteasome, selectively targets the LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP7/mLMP7) subunits of the immunoproteasome. Zetomipzomib has the potential for the research of multiple autoimmune diseases .
loading...
    loading...
4
4 Cited Publications
Art. -Nr.: HY-114419A
CAS. Nr.: 2170983-62-5
Reinheit:  99.84%
Synonyms: KZR-616 maleate
Target:  

Proteasome

Forschungsgebiete:  

Inflammation/Immunology

Zetomipzomib (KZR-616) maleate, a first-in-class immunoproteasome inhibitor, selectively targets the LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP2/mLMP2) subunits of the immunoproteasome. Zetomipzomib maleate has the potential for the research of multiple autoimmune diseases .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-12113
CAS. Nr.: 935888-69-0
Reinheit:  99.76%
Synonyms: ONX 0912; PR-047
Forschungsgebiete:  

Cancer

Oprozomib (PR-047) is an orally bioavailable and selective peptide epoxyketone proteasome inhibitor with IC50s of 36 and 82 nM for proteasome (β5) and immunoproteasome (LMP7), respectively. Oprozomib (ONX 0912) induces apoptosis in MM cells .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-114170
CAS. Nr.: 1140517-08-3
Reinheit:  ≥98.0%
Target:  

Proteasome

Forschungsgebiete:  

Inflammation/Immunology

ML604440 is a specific and cell-permeable Proteasome β1i (LMP2) subunit inhibitor. ML604440 can be used in experimental colitis, EAE and autoimmune disease research. ML604440 shows synergistic effects and advantageous when combined with LMP7 inhibitor .
loading...
    loading...
Art. -Nr.: HY-18351
CAS. Nr.: 915303-09-2
Synonyms: LMP-400; NSC-724998
Target:  

Topoisomerase

Forschungsgebiete:  

Infection Cancer

Indotecan (LMP-400), an indenoisoquinoline derivative, is a potent Topoisomerase I inhibitor, with IC50s of 300, 1200, 560 nM for P388, HCT116, MCF-7 cell lines, respectively. Indotecan prevents the relaxation of supercoiled DNA and can be used for the research of visceral leishmaniasis .
loading...
    loading...
Art. -Nr.: HY-U00248A
CAS. Nr.: 308246-57-3
Synonyms: MJ-III65 hydrochloride; NSC706744 hydrochloride
Target:  

Topoisomerase

Forschungsgebiete:  

Cancer

LMP744 hydrochloride (MJ-III65 hydrochloride) is a DNA intercalator and Topoisomerase I (Top1) inhibitor with antitumor activity .
loading...
    loading...
Art. -Nr.: HY-P11306
CAS. Nr.: 247068-92-4
Target:  

Proteasome NF-κB

Forschungsgebiete:  

Inflammation/Immunology

Biotin-(Oaa)3-epoxomicin is a biotin-labeled form of Epoxomicin (HY-13821), prepared by conjugating Epoxomicin with biotin via three hydrophilic oxaacetyl amino acid (Oaa) linkers. Biotin-(Oaa)3-epoxomicin is primarily used in proteomic studies for the capture, identification and target validation of proteasome complexes, to determine the intracellular targets of epoxomicin. Epoxomicin acts as a proteasome inhibitor and NF-κB inhibitor, which effectively blocks inflammatory responses in mouse ear edema assays. It inhibits proteasome activity via covalent binding to catalytic subunits including LMP7, X, MECL1 and Z, with the strongest inhibitory effect on chymotrypsin-like activity, and does not interfere with non-proteasomal proteases such as trypsin and papain .
loading...
    loading...
Art. -Nr.: HY-U00248
CAS. Nr.: 308246-52-8
Synonyms: MJ-III65; NSC706744
Target:  

Topoisomerase

Forschungsgebiete:  

Cancer

LMP744 (MJ-III65) is a DNA intercalator and Topoisomerase I (Top1) inhibitor with antitumor activity .
loading...
    loading...
Art. -Nr.: HY-123587
CAS. Nr.: 1416709-79-9
Reinheit:  98.87%
Target:  

Proteasome Apoptosis

Forschungsgebiete:  

Cancer

PR-924 is a selective tripeptide epoxyketone immunoproteasome subunit LMP-7 inhibitor with an IC50 of 22 nM. PR-924 covalently modifies proteasomal N-terminal threonine active sites. PR-924 inhibits growth and triggers apoptosis in multiple myeloma (MM) cells. PR-924 has antitumor activities .
loading...
    loading...
Art. -Nr.: HY-119037
CAS. Nr.: 1000313-40-5
Reinheit:  99.58%
Target:  

Proteasome Apoptosis

Forschungsgebiete:  

Cancer

UK-101 is a potent and selective immunoproteasome β1i (LMP2) inhibitor with an IC50 value of 104 nM, displays 144- and 10-fold selectivity over β1c (IC50=15 μM) and β5 subunit (IC50=1 μM), respectivey . UK-101 induces cell apoptosis and can be used for the study of prostate cancer .
loading...
    loading...
Art. -Nr.: HY-P5470
CAS. Nr.: 152274-91-4
Target:  

EBV IFNAR

Forschungsgebiete:  

Inflammation/Immunology

LMP2A (426-434) is a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). LMP2A (426-434) can trigger an immune response in individuals expressing different HLA-A*02 subtypes (A*02:01, A*02:03, A*02:06 and A*02:07). LMP2A (426-434) can induce a strong IFN-γ secretion response, stimulating the production of a high proportion of CD8 + IFN-γ + T cells. LMP2A (426-434) induces specific CTLs to effectively kill target cells expressing LMP2A. LMP2A (426-434) can be used to study EBV-related malignant tumors (such as Hodgkin's disease and nasopharyngeal carcinoma) .
loading...
    loading...
Art. -Nr.: HY-160005
CAS. Nr.: 1883730-99-1
Synonyms: NSC 781517
Forschungsgebiete:  

Cancer

LMP517 (NSC 781517) is a potent and non-camptothecin Topoisomerase I and II (TOP1 and TOP2) dual inhibitor. LMP517 can induce TOP1 and TOP2 cleavage complexes (TOP1ccs and TOP2ccs). LMP517 can induce cancer cells DNA damage and γH2AX production. LMP517 can be used for the research of cancer, such as small cell lung cancer .
loading...
    loading...
Art. -Nr.: HY-18350
CAS. Nr.: 915360-05-3
Synonyms: LMP776
Target:  

Topoisomerase

Forschungsgebiete:  

Cancer

Indimitecan (LMP776) is a topoisomerase I (Top1) inhibitor with anticancer activities .
loading...
    loading...
Art. -Nr.: HY-123052
CAS. Nr.: 1431362-79-6
Reinheit:  ≥97.0%
Target:  

Proteasome

Forschungsgebiete:  

Inflammation/Immunology

Ac-PAL-AMC is a fluorogenic substrate specific for 20S proteasome LMP2/β1i activity .
loading...
    loading...
Art. -Nr.: HY-129746
CAS. Nr.: 1630743-73-5
Reinheit:  99.20%
Target:  

Apoptosis

Forschungsgebiete:  

Cancer

Arylquin 1, a prostate-apoptosis-response-4 (Par-4) secretagogue, targets vimentin to induce Par-4 secretion. Arylquin 1 induces non-apoptotic cell death in cancer cells through the induction of lysosomal membrane permeabilization (LMP) .
loading...
    loading...